Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers

Autor: Andrea Mazzanti, Deni Kukavica, Alessandro Trancuccio, Mirella Memmi, Raffaella Bloise, Patrick Gambelli, Maira Marino, Martín Ortíz-Genga, Massimo Morini, Nicola Monteforte, Umberto Giordano, Roberto Keegan, Luca Tomasi, Aristides Anastasakis, Andrew M. Davis, Wataru Shimizu, Nico A. Blom, Demetrio Julián Santiago, Carlo Napolitano, Lorenzo Monserrat, Silvia G. Priori

Publikováno v: JAMA Cardiol
JAMA cardiology, 7(5), 504-512. American Medical Association
JAMA Cardiology, 7(5), 504-512. AMER MEDICAL ASSOC
Mazzanti, A, Kukavica, D, Trancuccio, A, Memmi, M, Bloise, R, Gambelli, P, Marino, M, Ortíz-Genga, M, Morini, M, Monteforte, N, Giordano, U, Keegan, R, Tomasi, L, Anastasakis, A, Davis, A M, Shimizu, W, Blom, N A, Santiago, D J, Napolitano, C, Monserrat, L & Priori, S G 2022, ' Outcomes of Patients with Catecholaminergic Polymorphic Ventricular Tachycardia Treated with β-Blockers ', JAMA cardiology, vol. 7, no. 5, pp. 504-512 . https://doi.org/10.1001/jamacardio.2022.0219

Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) may experience life-threatening arrhythmic events (LTAEs) despite β-blocker treatment. Further complicating management, the role of implantable cardioverter defibrillator (IC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c929e7cc08bf8cf5e5f9c580b72e5d54
https://europepmc.org/articles/PMC8968697/